Stem Cells and PRP in Women's Health: Menopause, Intimate Health and Ovarian Claims

A field where marketing outpaced the science

Women's intimate and menopausal health has been genuinely neglected by medicine for a long time. Symptoms were dismissed as inevitable, research funding lagged, and many women reached midlife without ever being told that effective treatments existed. Into that vacuum arrived a wave of commercial offerings — branded injections, energy-based devices, "rejuvenation" packages — often marketed directly to women through channels that bypassed clinical scrutiny entirely.

Two things are true at once here, and both matter. The neglect was real and the frustration it created is justified. And the commercial response to that neglect has frequently been evidence-light, sometimes marketed with language implying restoration of youth rather than treatment of a specific condition. Women deserve better than both the old dismissal and the new sales pitch.

This article covers three distinct areas that often get bundled together: genitourinary syndrome of menopause, stress urinary incontinence, and ovarian rejuvenation claims related to fertility. They involve different tissues, different evidence bases and different risks of being misled, and separating them is the first useful step. Our hormone optimization article and fertility program cover related ground.

Genitourinary syndrome of menopause: proven treatment first

Genitourinary syndrome of menopause describes the changes that follow declining estrogen: vaginal dryness, thinning and reduced elasticity of tissues, discomfort or pain with intercourse, itching or burning, and urinary symptoms including urgency and recurrent urinary tract infections. It affects a very large proportion of postmenopausal women, and unlike hot flashes it does not resolve on its own — it tends to progress.

Here is the part that too few women are told: local vaginal estrogen therapy has strong evidence for this condition and is effective for the great majority. Delivered locally as a cream, tablet or ring, systemic absorption is low, and it directly addresses the underlying tissue change rather than masking a symptom. Non-hormonal options including vaginal moisturizers and lubricants also help, and other prescription options exist for women who cannot or prefer not to use estrogen. For women with a history of breast cancer or other specific circumstances, the decision requires individualized discussion with a specialist — but the conversation should happen rather than being avoided.

Against that backdrop, PRP injection for vaginal tissue, often sold under a branded name, is investigational. The published evidence consists largely of small studies, and systematic assessment has generally found it insufficient to establish the treatment. That does not mean it cannot help anyone; it means that spending significantly on an unproven injection while an effective, inexpensive, well-studied treatment has never been tried is a poor sequence. Ask any clinic offering the injection whether you have been evaluated for local estrogen therapy first, and treat the answer as informative.

Urinary incontinence and the treatment nobody sells

Stress urinary incontinence — leakage with coughing, laughing, sneezing or exercise — is common, under-reported and genuinely treatable. The intervention with the strongest evidence is not a procedure or an injection. It is supervised pelvic floor muscle training delivered by a physiotherapist with appropriate expertise, done properly over a period of months.

This matters because pelvic floor physiotherapy is consistently under-used relative to its evidence, partly because nobody markets it aggressively. There is no branded name, no seminar, no package. Yet for many women it produces meaningful or complete improvement, and it carries essentially no risk. Any assessment of incontinence that jumps to a procedure without a genuine trial of supervised pelvic floor training has skipped the most valuable step.

Cell therapy for stress urinary incontinence has actually been an area of legitimate research, with studies investigating whether cells injected into the urethral sphincter might improve function. Results have been mixed and it remains investigational. Established options beyond physiotherapy include pessaries, and for appropriate patients surgical procedures with well-documented outcomes. A urogynecological assessment is the right route for women who do not improve with conservative measures — and notably, regulators have previously issued warnings about energy-based "vaginal rejuvenation" devices marketed for these and related indications with claims that outran the evidence supporting them.

Ovarian rejuvenation: where skepticism should be highest

The most consequential claims in this field concern fertility. "Ovarian rejuvenation" refers to procedures — including PRP injection into the ovaries and various cell-based approaches — marketed to women with diminished ovarian reserve, premature ovarian insufficiency or repeated IVF failure, with the implication that ovarian function and egg quality can be restored.

The honest status is that this is experimental. Some small studies and case series have reported changes in hormonal markers or occasional pregnancies, and there is genuine scientific interest in the underlying biology. What does not exist is robust, well-controlled evidence that these procedures reliably improve live birth rates. Given that spontaneous pregnancy occasionally occurs even in women with poor prognosis, uncontrolled reports of individual successes are especially weak evidence.

This is an area where the emotional stakes are extremely high and the potential for exploitation correspondingly large. Women pursuing fertility treatment are often already financially and emotionally stretched, and an offer framed as a last chance is powerfully persuasive. Reasonable protections: involve your reproductive endocrinologist, ask whether the procedure is part of a registered study, ask for the specific published evidence supporting it in your situation, and be wary of any clinic presenting it as a way to avoid donor eggs when that is the medically indicated path. Our IVF success rates article covers how to interpret fertility statistics generally, and our egg donation guide explains an option that is sometimes dismissed prematurely.

How to evaluate offers in this space

A few questions cut through most of the marketing. Has a qualified physician assessed me and discussed the established treatments for my specific symptoms? Will you describe this treatment as investigational in writing? What published evidence supports this specific protocol for my condition? What outcome do you expect and how will we measure it? Am I being asked to prepay for multiple sessions before knowing whether one helps?

Warning signs include branded procedure names presented as validated medicine, marketing language about restoring youth or transforming intimate life rather than treating a defined condition, packages sold at events, testimonials in place of data, claims about fertility restoration, and any offer made without a proper gynecological assessment. The absence of assessment is the clearest signal, because these symptoms have specific causes that deserve diagnosis — including some, such as postmenopausal bleeding, that require prompt evaluation for reasons unrelated to comfort.

At HealthBridge, our medical director Dra. Olga González leads the longevity and regenerative program, therapies are administered by licensed physicians under Colombian regulations after individualized assessment, and we describe applications in women's intimate health as investigational because that is what the evidence supports. Where a woman has never been offered local estrogen therapy or pelvic floor physiotherapy, our honest guidance is to start there.

What we would tell a friend

If a friend asked about this directly, the advice would be short. Get properly assessed by a clinician who takes menopausal and intimate health seriously — this alone resolves a great deal, because the most common problem is not a lack of advanced options but a lack of basic ones being offered. Ask specifically about local estrogen therapy for genitourinary symptoms and about supervised pelvic floor physiotherapy for incontinence.

Give the proven treatments a real trial before spending on anything experimental. Local estrogen is inexpensive, well studied and effective for most women with genitourinary syndrome of menopause. Pelvic floor training costs a fraction of any procedure. Both are undramatic, which is precisely why they are under-marketed and under-used.

And be most careful where hope is highest. Fertility claims deserve the greatest scrutiny, because the emotional and financial stakes make women vulnerable to offers framed as a final chance. If you do choose to explore regenerative options after the established ones, do so knowingly, with a licensed physician, with your own specialist informed, and without prepaying for a package. For the wider science, our pillar guide to stem cell therapy in Colombia explains what these therapies actually do, and our regenerative medicine program sets out where we believe the evidence genuinely supports them.